Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of ivonescimab plus platinum-doublet chemotherapy in first-line SMARCA4-deficient advanced NSCLC
ChiCTR2500099104Phase 2Not yet recruiting
- Sponsor
- Liaoning Province Cancer Hospital
- Start
- Mar 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab in non-small cell lung cancer (NSCLC), sponsored by Liaoning Province Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500099104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099104.